Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06027047

Acronym

BASEL

Enrollment

Registered

2023-09-07

Start date

2023-09-01

Completion date

2024-01-15

Last updated

2023-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders, Depression, Anxiety, Depressive Symptoms, Sleep Deprivation, Sleep Driving, Sleep Hygiene, Sleepiness

Keywords

smartphone, wearables, app, sleep, anxiety, depression

Brief summary

Sleep is not simply the absence of wakefulness. Sleep is an active procedure, normally happening every night, and is absolutely vital. Good sleep is essential for our well-being. Survival without food can be further than without sleep. Work time and commuting time seem to affect total sleep time and night bedtime. Social and work obligation can, therefore, suppress sleep time. Sleep deprived individuals may be facing anxiety and depression symptoms. The aim of this study is to investigate the presence of anxiety and depression symptoms among adults with the use of the smartphone application Onar. Onar app will be used to gather information from wearable devices of the users including total sleep time, sleep efficiency, wake after sleep onset time. An established questionnaire (Hospital Anxiety Depression Scale/ HADS) will be used to quantify and detect the presence of anxiety and depression in the study population.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Acceptance of terms of use of the application must be done prior to participation in the study. * Male and female adults aged ≥18 years old and ≤60 years old. * Subjects using the application on a daily basis for at least 1 week prior to participation.

Exclusion criteria

* History of alcohol or other substance abuse.

Design outcomes

Primary

Measure	Time frame	Description
To determine the existence of depression and anxiety symptoms in the study population.	2 weeks	Comparison of HADS score with population standardized mean value.

Secondary

Measure	Time frame	Description
Correlation of depression and anxiety symptoms with Total sleep time (TST).	2 weeks	Total sleep time (TST).
Correlation of depression and anxiety symptoms with Wake after sleep onset time (WASO).	2 weeks	Wake after sleep onset time (WASO).
Correlation of depression and anxiety symptoms with Sleep Onset Latency (SOL).	2 weeks	Sleep Onset Latency (SOL).
Correlation of depression and anxiety symptoms with Epworth Sleepiness Scale (ESS).	2 weeks	Epworth Sleepiness Scale (ESS).

Contacts

Primary ContactEmmanouil Bakopoulos, MSc

info@raivotech.com+306945108313

Outcome results